Last updated: 2026-09-07 16:38:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Arrowhead Research Corporation (ARWR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $86.41, with a market capitalisation of $12.20B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $27.10 to $95.49. This page covers its latest market performance, valuation, price trends and company information.
$12.20B | |
$85.87 | |
$95.49 | |
$1.20 | |
$86.49 | |
610.51K | |
2.00M | |
-- | |
$95.49 | |
$27.10 | |
0.32% | |
-- |
Arrowhead Research Corporation (ARWR) last closed at $86.49 as of 2026-09-04 23:31:00, unchanged from the previous close of $86.49.
During the latest regular trading session, ARWR traded between $1.20 and $95.49, with a volume of 610.51K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Arrowhead Research Corporation (ARWR) moved from $88.59 to $86.41, representing a decline of 2.46% ($2.18).
The stock traded between $80.75 and $89.59 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.25 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 86.7%
ARWR is currently trading at $86.41, placing it 86.7% of the way from its 52-week low of $27.10 to its 52-week high of $95.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 711 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arrowhead Research Corporation (ARWR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.